TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21762787

Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0
Study: 19348303

Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stents
Number of subjects: 108
Study: 16689620

Group type: EXPERIMENTAL
Intervention: Elliptical cross-trainer submaximal test
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Predicted VO2max
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cross-validation of prediction equation
Number of subjects: 54
Study: 15236892

Group type: EXPERIMENTAL
Intervention: Tonsillectomy and adenoidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy children with normal ENT examination)
Number of subjects: 0
Study: 11099757

Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS) - pure tone with unconditioned stimulus (US) - loud white noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS) - pure tone with unconditioned stimulus (US) - loud white noise after five preexposures to the CS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS) - pure tone with unconditioned stimulus (US) - loud white noise after two preexposures to the CS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with non-contingent CS and US presentation
Number of subjects: 0
Study: 9448645

Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation (TCS) of affected hemisphere (AH)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation (TCS) of unaffected hemisphere (UH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Focal transcranial magnetic stimulation (TCS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neurorehabilitation
Number of subjects: 18
Study: 8173018

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 53
Study: 3169371

Group type: EXPERIMENTAL
Intervention: 200 mg standard release disopyramide given three times daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 250 mg sustained release disopyramide given twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal ventricular function)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (abnormal ventricular function)
Number of subjects: 20
Study: 29445831

Group type: EXPERIMENTAL
Intervention: Minimal intervention (MIN)
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Intensive intervention (INT)
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Specialized group (SPE)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 1086
Study: 27110697

Group type: EXPERIMENTAL
Intervention: Sirukumab (10 mg/kg intravenously every 4 weeks through week 24)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (4 patients)
Number of subjects: 25
Study: 26450545

Group type: EXPERIMENTAL
Intervention: Small financial incentives (maximum $5.00 per week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-incentive condition
Number of subjects: 22
Study: 22795712

Group type: EXPERIMENTAL
Intervention: Immediate catheterization strategy
Number of subjects: 345

Group type: COMPARATOR
Intervention: Delayed catheterization strategy
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Patients with IRF
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Delayed strategy in patients with IRF
Number of subjects: 345
Study: 21565321

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 19064574

Group type: EXPERIMENTAL
Intervention: Flaxseed-supplemented diet (30 g/d)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Flaxseed-supplemented, low-fat diet
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control (usual diet)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Low-fat diet (<20% total energy)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 161
Study: 17073955

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits
Number of subjects: 36

Group type: COMPARATOR
Intervention: PMEA-coated CPB circuits
Number of subjects: 36
Study: 14520146

Group type: EXPERIMENTAL
Intervention: Linezolid (10 mg/kg for patients <12 years; 600 mg for patients ≥12 years, intravenous/oral, 2-3 times daily)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 958
Study: 10901647

Group type: EXPERIMENTAL
Intervention: Reamed technique
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Unreamed technique
Number of subjects: 11
Study: 9100721

Group type: EXPERIMENTAL
Intervention: Patient Self‐Determination Act (PSDA)
Number of subjects: 9105

Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 9105

Group type: EXPERIMENTAL
Intervention: Advance directives (ADs)
Number of subjects: 9105

Group type: COMPARATOR
Intervention: No advance directive (AD)
Number of subjects: 9105
Study: 7967990

Group type: EXPERIMENTAL
Intervention: Oral inactivated whole-cell/recombinant-B-subunit cholera vaccine (WC/rBS)
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Escherichia coli K12 placebo
Number of subjects: 1563
Study: 3304929

Group type: COMPARATOR
Intervention: ranitidine 300 mg at night
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at night + 200 mg ofloxacin twice daily
Number of subjects: 50
Study: 31732740

Group type: EXPERIMENTAL
Intervention: Vitamin D intake (median (IQR) = 586 (459, 859) IU/d in early pregnancy)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Vitamin D intake (median (IQR) = 689 (544, 974) IU/d in late pregnancy)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Serum 1,25(OH)2D concentrations
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Maternal vitamin D status in early pregnancy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Maternal vitamin D status in late pregnancy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cord serum 25(OH)D concentrations
Number of subjects: 187
Study: 29912623

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 102
Study: 27208667

Group type: EXPERIMENTAL
Intervention: Combined intervention (nutrition education and environmental dietary modification)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 541

Group type: COMPARATOR
Intervention: Environmental dietary modification intervention
Number of subjects: 541

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 541
Study: 24615309

Group type: EXPERIMENTAL
Intervention: Raw milk
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pasteurized milk
Number of subjects: 16

Group type: COMPARATOR
Intervention: Soy milk
Number of subjects: 16
Study: 21797979

Group type: EXPERIMENTAL
Intervention: Tongue scraping
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Tongue brushing
Number of subjects: 3

Group type: COMPARATOR
Intervention: Tooth brushing only
Number of subjects: 3
Study: 20683089

Group type: EXPERIMENTAL
Intervention: Nonelimination games
Number of subjects: 29

Group type: COMPARATOR
Intervention: Elimination games
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both game sessions
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both game types
Number of subjects: 29
Study: 18650827

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 or 100 mg) nightly for 36 weeks
Number of subjects: 76
Study: 16647885

Group type: EXPERIMENTAL
Intervention: Hibernating myocardium and/or inhomogeneity of sympathetic innervation identified by positron emission tomography imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic cardiac positron emission tomography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone follow-up every three months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appropriate device discharge in patients with an implantable cardiac defibrillator
Number of subjects: 0
Study: 14744352

Group type: EXPERIMENTAL
Intervention: Stented group (N = 26)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonstented group (N = 22)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 10815785

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 132
Study: 8625230

Group type: EXPERIMENTAL
Intervention: PAM (cisplatin 60 mg/m2 i.v. on Days 1 and 29; doxorubicin 30 mg/m2 i.v. on Days 1 and 29; mitomycin C 10 mg/m2 i.v. on Day 1; every 8 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: FAM (5‐fluorouracil 600 mg/m2 i.v. on Days 1, 8, 29, 36; doxorubicin 30 mg/m2 i.v. on Days 1 and 29; mitomycin C 10 mg/m2 i.v. on Day 1; every 8 weeks)
Number of subjects: 102
Study: 1483854

Group type: EXPERIMENTAL
Intervention: CBDCA + BCNU + VP‐16
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CBDCA + BCNU
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CDDP + VP‐16
Number of subjects: 84

Group type: COMPARATOR
Intervention: BCNU alone
Number of subjects: 84
Study: 3158783

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Membrane oxygenator
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 30196973

Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Water-based contrast
Number of subjects: 1119
Study: 26799540

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 25171742

Group type: EXPERIMENTAL
Intervention: Education programme for parents of children with AD
Number of subjects: 274
Study: 23631796

Group type: EXPERIMENTAL
Intervention: Inhaled glutathione (646 mg in 4 ml) administered every 12 hours for 6 months
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 20801246

Group type: EXPERIMENTAL
Intervention: Neck manipulation
Number of subjects: 182

Group type: COMPARATOR
Intervention: Mobilization
Number of subjects: 182
Study: 19169063

Group type: EXPERIMENTAL
Intervention: Group Care
Number of subjects: 25
Study: 15837905

Group type: EXPERIMENTAL
Intervention: Brandt‐Daroff exercises (treatment group, n = 43)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No exercises (no-treatment group, n = 73)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Brandt‐Daroff exercises (treatment group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No exercises (no-treatment group)
Number of subjects: 116
Study: 12898489

Group type: EXPERIMENTAL
Intervention: ED group (received azithromycin from the ED)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Pharmacy group (prescription for azithromycin to be filled at a local pharmacy)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ED group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Pharmacy group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ED group and Pharmacy group
Number of subjects: 74
Study: 10566643

Group type: EXPERIMENTAL
Intervention: Dietary soy supplementation (60 g, 45 mg isoflavones)
Number of subjects: 84
Study: 8739813

Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg tablet, three times daily for 3 months (TID group)
Number of subjects: 7274

Group type: COMPARATOR
Intervention: Slow release nicardipine, 50 mg twice daily for 3 months (BID group)
Number of subjects: 7274
Study: 2065042

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking and jogging)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonaerobic strength exercise (circuit Nautilus training)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (aerobic and nonaerobic)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 50
Study: 7014726

Group type: EXPERIMENTAL
Intervention: new chromone compound
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 28
Study: 30871947

Group type: EXPERIMENTAL
Intervention: Lacritose (50g)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Glucose (50g)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sucrose (50g)
Number of subjects: 41
Study: 27616436

Group type: EXPERIMENTAL
Intervention: Providing clinic correspondence and endoscopy reports to patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: No correspondence provided (Control)
Number of subjects: 70
Study: 26871534

Group type: EXPERIMENTAL
Intervention: Negative hypnotic suggestions (based on the Pain Catastrophizing Scale)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Positive hypnotic suggestions (coping-oriented reversion of the Pain Catastrophizing Scale)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neutral hypnotic suggestions (neutral sentence)
Number of subjects: 44
Study: 24345453

Group type: EXPERIMENTAL
Intervention: nCPAP at 4 cm H2O
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: nCPAP at 6 cm H2O
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: nCPAP at 8 cm H2O
Number of subjects: 34
Study: 22709750

Group type: EXPERIMENTAL
Intervention: Behavioral management intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication management intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined intervention (for patients with poor baseline BP control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19351830

Group type: EXPERIMENTAL
Intervention: HPV16-positive CIN3+
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: HPV18/45-positive CIN3+
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: CIN3 positive for other carcinogenic HPV types
Number of subjects: 412
Study: 17479605

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 28
Study: 15727381

Group type: EXPERIMENTAL
Intervention: Zolterol, SR (generic diclofenac sodium sustained release tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Voltaren, SR (innovator product)
Number of subjects: 12
Study: 12080409

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (Sat) test meal
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trans fatty acids (Trans) test meal
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison of Sat and Trans meals
Number of subjects: 21
Study: 9534106

Group type: EXPERIMENTAL
Intervention: slow-release verapamil 240 mg/day
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: trandolapril 2 mg/day
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: verapamil 180 mg/day plus trandolapril 2 mg/day
Number of subjects: 2400

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: trandolapril 2 mg/day plus verapamil 180 mg/day
Number of subjects: 2400
Study: 7661587

Group type: EXPERIMENTAL
Intervention: Best supportive care plus combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 2693623

Group type: EXPERIMENTAL
Intervention: Piperacillin alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triple antibiotic combination (gentamicin, clindamycin, penicillin G)
Number of subjects: 40
Study: 668934

Group type: EXPERIMENTAL
Intervention: Artificial insemination with donor semen (AID)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fresh semen
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Age group 25 to 30
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: History of previous pregnancy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Age 31 or older
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pelvic disease
Number of subjects: 114

Group type: COMPARATOR
Intervention: Freshly thawed semen
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Surgically correctable pelvic disease treated
Number of subjects: 114

Group type: COMPARATOR
Intervention: Vaginal device for retaining semen
Number of subjects: 114

Group type: COMPARATOR
Intervention: Patient positioning
Number of subjects: 114

Group type: COMPARATOR
Intervention: Duration of infertility
Number of subjects: 114
Study: 31357965

Group type: EXPERIMENTAL
Intervention: Mindfulness-based social cognition training (SocialMIND)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Psychoeducational multicomponent intervention (PMI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SocialMIND
Number of subjects: 80

Group type: COMPARATOR
Intervention: PMI
Number of subjects: 80
Study: 28537195

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg-1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 25801408

Group type: EXPERIMENTAL
Intervention: Ivabradine (7.5 mg b.i.d.)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 602
Study: 23828185

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (10 sessions, 30-45 minutes each)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care (exercise and education)
Number of subjects: 146
Study: 21441549

Group type: EXPERIMENTAL
Intervention: Remifentanil patient-controlled analgesia (PCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine patient-controlled analgesia (PCA)
Number of subjects: 0
Study: 19363377

Group type: EXPERIMENTAL
Intervention: Psychosocial treatment for MA dependence
Number of subjects: 526

Group type: COMPARATOR
Intervention: Major depression at follow-up
Number of subjects: 526
Study: 17601318

Group type: EXPERIMENTAL
Intervention: NNT (Number Needed to Treat)
Number of subjects: 0
Study: 15611540

Group type: COMPARATOR
Intervention: Local anaesthesia (lidocaine 1% with adrenaline 1:100 000)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (lidocaine 1% with adrenaline 1:100 000)
Number of subjects: 36
Study: 12095667

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 120, 240, and 480 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7924721

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 95

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 95
Study: 2530546

Group type: EXPERIMENTAL
Intervention: IV ceftriaxone 2 g daily for 4 days, followed by IM or IV ceftriaxone 1 g daily for 11 days
Number of subjects: 95

Group type: COMPARATOR
Intervention: IV ceftriaxone 2 g every other day for 4 days, followed by oral cefixime 200 mg twice daily for 11 days
Number of subjects: 95
Study: 29509051

Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 0
Study: 27130929

Group type: EXPERIMENTAL
Intervention: Oncotype DX
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Prosigna (PAM50)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: IHC4
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: MammaPrint
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: NexCourse Breast
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Subtype tests (Blueprint, MammaTyper, Prosigna)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Overall risk categorization
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Discordant subtyping
Number of subjects: 313
Study: 25769319

Group type: EXPERIMENTAL
Intervention: Ji‐Tai tablet
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ji‐Tai tablet combined with buprenorphine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 23810466

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + S-1 (paclitaxel 60 mg/m2 on days 1, 8, and 15; S-1 80-120 mg/d on days 1-14)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + S-1
Number of subjects: 240

Group type: COMPARATOR
Intervention: Weekly paclitaxel + 5-fluorouracil (paclitaxel 60 mg/m2; 5-fluorouracil 500 mg/m2 on days 1-5; leucovorin 20 mg/m2 on days 1-5)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Weekly paclitaxel + 5-fluorouracil
Number of subjects: 240
Study: 20587723

Group type: EXPERIMENTAL
Intervention: 2-h hyperinsulinemic hypoglycemia (2.9 ± 0.1 mmol/l)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Euglycemia (5.2 ± 0.1 mmol/l)
Number of subjects: 59
Study: 18249205

Group type: EXPERIMENTAL
Intervention: 22 mg PSs per kilogram of body weight with a low‐cholesterol diet (C(‐)S(+))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 22 mg PSs per kilogram of body weight with a high‐cholesterol diet (C(+)S(+))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low‐cholesterol control (C(‐)S(‐))
Number of subjects: 22

Group type: COMPARATOR
Intervention: High‐cholesterol control (C(+)S(‐))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 22 mg PSs per kilogram of body weight (both diets)
Number of subjects: 22
Study: 16324316

Group type: EXPERIMENTAL
Intervention: H. pylori-positive individuals (1603 subjects)
Number of subjects: 2469

Group type: COMPARATOR
Intervention: H. pylori-negative individuals (866 subjects)
Number of subjects: 2469

Group type: EXPERIMENTAL
Intervention: H. pylori-positive with chronic gastritis (CAG)
Number of subjects: 2469

Group type: EXPERIMENTAL
Intervention: H. pylori-positive with intestinal metaplasia (IM)
Number of subjects: 2469

Group type: EXPERIMENTAL
Intervention: H. pylori-positive with dysplasia (DYS)
Number of subjects: 2469
Study: 12628943

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 14
Study: 10389720

Group type: EXPERIMENTAL
Intervention: Weekly stress incontinence
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Weekly urge incontinence
Number of subjects: 2763
Study: 8696060

Group type: EXPERIMENTAL
Intervention: TEE‐dobutamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thallium‐201‐dipyridamole scintigraphy (TDS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 30
Study: 1988575

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy and tamoxifen)
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (tamoxifen and chemotherapy)
Number of subjects: 2673

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 2673